Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $10.82, for a total transaction of $21,640.00. Following the transaction, the president now owns 2,936,467 shares of the company’s stock, valued at $31,772,572.94. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Songjiang Ma also recently made the following trade(s):

• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Trading Up 9.5 %

GYRE traded up $1.06 on Monday, hitting $12.20. The company had a trading volume of 111,450 shares, compared to its average volume of 75,000. The business’s fifty day simple moving average is $12.86 and its 200 day simple moving average is $12.61. Gyre Therapeutics, Inc. has a 12-month low of $8.26 and a 12-month high of $30.39.

Hedge Funds Weigh In On Gyre Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC bought a new position in Gyre Therapeutics during the 3rd quarter valued at about $47,000. Barclays PLC grew its stake in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after buying an additional 6,855 shares during the last quarter. Rhumbline Advisers purchased a new stake in shares of Gyre Therapeutics in the second quarter worth approximately $123,000. Renaissance Technologies LLC bought a new stake in shares of Gyre Therapeutics during the 2nd quarter worth approximately $166,000. Finally, Bank of New York Mellon Corp purchased a new position in Gyre Therapeutics during the 2nd quarter valued at $218,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.